A narrative review of systemic treatment options for hepatocellular carcinoma: state of the art review

Abstract

Hepatocellular carcinoma (HCC) is an aggressive cancer that typically develops in the setting of underlying cirrhosis of the liver. HCC commonly presents in advanced stages and if eligible orthotopic liver transplantation (OLT) and surgical resection/ablation remain as the only curative options. Prior to 2007, no systemic therapy was available that demonstrated an improvement in survival. Underlying cirrhosis and poor synthetic hepatic function provides a major challenge into effective systemic options contributing to the poor success of cytotoxic chemotherapy in HCC. The first drug to achieve clinical success was sorafenib despite the underwhelming overall survival of 3 months. Since then, other targeted therapies have shown modest benefit as well. Most recently, immunotherapy advances have come to the forefront in the management of HCC and combination therapy with immunotherapy and monoclonal antibodies have now surpassed sorafenib as first line treatment. This article will review the various approved and emerging therapies that have had a significant clinical impact and highlight the future directions and ongoing research that will hopefully translate into better outcomes in the treatment approach of advanced HCC.

Introduction

Hepatocellular carcinoma (HCC) accounts for 90% of primary liver cancers and is the fourth-leading cause of cancer-related deaths worldwide despite multiple treatment modalities that have emerged over the years (1,2). In the United States it is projected that by 2040, HCC will be the third-leading cause of cancer-related death, surpassing breast cancer with an estimated 41,000 deaths per year (3). Incorporation of effective surveillance programs has led to early detection in 40–50% of HCC making them amenable to early-stage curative therapies such as resection, local ablation, and liver transplantation (4,5). However, despite diligent surveillance programs, a substantial proportion of HCC diagnoses are still made in the advanced stages (6). Non-curative options have consisted of locoregional therapies in intermediate unresectable disease and systemic therapies in advanced disease. Systemic therapies have been driven by the evolution in molecular biology of cancer with the advent of sorafenib in 2007 launching a new era into targeted therapies. Since then, other targeted therapies have been shown to improve clinical outcomes in HCC. More recently, immunotherapy has made considerable progress in HCC treatment. Here, we review systemic therapies, with a focus on recent advances. We present the following article in accordance with the Narrative Review reporting checklist (available at https://jgo.amegroups.com/article/view/10.21037/jgo-21-274/rc).

Methods

An online search of the literature utilizing google scholar, PubMed, Cochrane library and science direct was employed. Selection criteria included advanced or unresectable HCC, targeted therapies, immunotherapy, randomized clinical trials from 2007 to April 2021.

Tyrosine kinase inhibitors (TKI)

Since the discovery of imatinib in 2001, TKIs have rapidly evolved and emerged as approved targeted therapies in various cancers. Protein tyrosine kinase (PTK) is a class of proteins involved in cell signaling and differentiation. The tyrosine kinase activity catalyzes the transfer of phosphate groups on ATP to the tyrosine residues of many important proteins, making proteins phosphorylation, then transferring signal to regulate cell growth, differentiation, death and a series of physiological and biochemical processes (7). Common receptor tyrosine kinases (RTKs) targeted in tumorigenesis are epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR) and insulin receptor (INsR). They typically have an extracellular domain that binds to specific ligands causing a series of biochemical reactions resulting in cellular proliferation (Figure 1). Proto-oncogenes and oncogenes are found to be associated with mutated or abnormal expression of PTKs and play a significant role in cancer growth manifested by tumor invasion and metastasis, tumor neovascularization and tumor chemotherapy resistance (7). This became the main driver behind various research and clinical trials and the discovery of TKIs in the treatment of cancers. It wasn’t very long that TKIs in HCC treatment heralded the discovery of sorafenib in 2007 and subsequent various other TKIs that have shown promising outcomes in HCC treatment (Table 1).

Figure 1.

Schematic model of tumorigenic signaling pathways and their inhibition by anti-cancer-TKI. The figure is reused from the article below Eckstein N, Röper L, Haas B, et al. Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective. J Exp Clin Cancer Res 2014;33:15.

Table 1. Lists a summary of the TKI’s that are FDA approved in advanced HCC.

Trial name	Author	No. of patients	Study arm	ECOG	Child-Pugh score	BCLC stage	Primary endpoint
SHARP	Llovet et al. (5)	602	Sorafenib vs. placebo (first-line setting)	0 to 2	A	B	OS: 10.7 vs. 7.9 months; hazard ratio (HR) =0.69; P<0.001; TTP: 4.1 vs. 4.9 months, P=0.77
REFLECT	Kudo et al. (8)	954	Lenvantinib vs. sorafenib (first-line setting)	0 or 1	A	B or C	OS: lenvatinib 13.6 months (95% CI: 12.1–14.9) vs. sorafenib (12.3 months, 95% CI: 10.4–13.9) (HR =0.92, 95% CI: 0.79–1.06)
CELESTIAL	Abou-Alfa et al. (9)	707	Cabozantinib vs. placebo (second-line setting)	0 or 1	A		OS: cabozantinib 10.2 vs. 8.0 months with placebo (HR =0.76; 95% CI: 0.63–0.92; P=0.005)
RESORCE	Bruix et al. (10)	567	Regorafenib vs. placebo (second-line setting)	0 or 1	A	B or C	OS: 10.6 months (95% CI: 9.1–12.1) for regorafenib vs. 7.8 months (6.3–8.8) for placebo, HR =0.63 (95% CI: 0.50–0.79; P<0.0001)

TKI, tyrosine kinase inhibitors; HCC, hepatocellular carcinoma; OS, overall survival; HR, hazard ratio.

Sorafenib

Prior to 2007 there weren’t any effective systemic treatment options available for advanced HCC. The SHARP trial brought to the forefront sorafenib, a multikinase inhibitor that targets VEGF, PDGF and Raf receptors inhibiting tumor-cell proliferation, tumor angiogenesis and increasing the rate of apoptosis (Figure 1). This multicenter, double blinded placebo-controlled trial enrolled 602 patients with advanced HCC who hadn’t received prior systemic therapy were assigned to sorafenib 400 mg twice a day or placebo. Primary outcomes were overall survival (OS) and time to symptomatic progression with secondary endpoints of radiological progression and safety. Results from the trial showed a median OS nearly 3 months longer compared with the placebo group [10.7 vs. 7.9 months; hazard ratio (HR) =0.69; P<0.001] (5). With the success of sorafenib and the focus of targeting antiangiogenic pathways in HCC various targeted therapies have since been investigated but failed to produce superiority or noninferiority compared with sorafenib (Table 2). Over the years phase I/II trials have studied dovitinib, vandetanib, pazopanib, orantinib, tivantinib, nintedanib, foretinib in the first-line setting without success.

Table 2. lists the main phase III trials that failed to demonstrate noninferiority to sorafenib.

Source	Phase	No. of patients	Year	TKI	Target population	Study arms	Primary endpoint	OS (months)
Cheng (11)	III	1,073	2011	Sunitinib-inhibits VEGFR, PDGFR, c-KIT, FTR-3	Advanced HCC	Sunitinib	OS	8.1
						Sorafenib		10
Johnson (12)	III	1,155	2012	Brivanib-inhibits VEGFR, FGF	Advanced HCC	Brivanib	OS	9.5
						Sorafenib		9.9
Cainap (13)	III	1,035	2012	Linifanib-inhibits PDGF, VEGFR	Advanced HCC	Linifanib	OS	9.1
						Sorafenib		9.8
Zhu (14)	III	720	2014	Erlotinib-inhibits EGFR	Advanced HCC	Erlotinib + sorafenib	OS	9.5
						Sorafenib + placebo		8.5

TKI, tyrosine kinase inhibitors; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet derived growth factor receptor; FGF, fibroblast growth factor; HCC, hepatocellular carcinoma; OS, overall survival.

After about 10 years of sorafenib being the mainstay of systemic therapy in HCC, lenvatinib demonstrated clinical benefit as well in the first-line setting. Lenvatinib is an oral multikinase inhibitor that targets VEGF receptors 1–3, PDGF receptor alpha, FGF receptors, RET and KIT (8). In an open-label, phase III, noninferiority, multicenter clinical trial, 954 eligible patients with unresectable or advanced HCC who had not received treatment for advanced disease were randomly assigned to receive lenvatinib or sorafenib. The primary endpoint of median OS was 13.6 months with lenvatinib compared with 12.3 months with sorafenib meeting criteria for noninferiority (HR =0.92, 95% CI: 0.72–1.06) (8). Secondary end points of median PFS was longer with lenvatinib (7.4 months) compared with sorafenib (3.7 months). similarly, a longer time to progression with lenvatinib revealed 8.4 months compared with 3.7 months with sorafenib. Lenvatinib also had an objective response rate (ORR) of 24.1% compared with 9.2% on sorafenib (8). Lenvatinib arm had fewer hand-foot-skin reactions, diarrhea, and alopecia events; the sorafenib arm had fewer hypertension, proteinuria, dysphonia, and hypothyroidism events. Overall, the study concluded that lenvatinib was non-inferior to sorafenib as a first-line treatment in advanced HCC.

Lenvatinib and sorafenib are both FDA-approved as first-line therapies in advanced HCC. The decision on which therapy to use is left to the discretion of the physician with lenvatinib demonstrating noninferiority to sorafenib in overall survival per the REFLECT trial (8). Lenvatinib had superior secondary end points of PFS, TTP and RR compared with sorafenib (8,15). Sorafenib has been around for over 10 years leading to more experience and familiarity with its use. Safety profile was comparable for the two agents, with lenvatinib better tolerated with regard to diarrhea, weight loss and hand-foot skin reactions and sorafenib causing less hypertension, hypothyroidism, and proteinuria (8). Subsequent clinical trials evaluating second-line therapeutic options have been conducted in the setting of prior sorafenib use and none yet in the setting of prior lenvatinib therapy (15).

Cabozantinib

In patients who have been previously treated with sorafenib and developed disease progression on at least one systemic therapy, cabozantinib, a multikinase inhibitor, has shown clinical activity and promising outcomes in advanced HCC (9). Cabozantinib targets VEGF, MET and AXL receptors. MET and AXL receptors have been implicated in antiangiogenic resistance in addition to epithelial-mesenchymal transition, invasion, and metastasis (9). Poor prognosis in HCC has been associated with high expression of MET and AXL with increased MET activity seen in previously treated patients on sorafenib who develop resistance (9). In this randomized, double-blinded phase III trial, 707 patients who had received prior treatment with sorafenib, had developed progression of disease on at least one systemic treatment for HCC, or received up to two previous systemic treatments, were enrolled to receive cabozantinib 60 mg daily vs. placebo (9). The primary endpoint was OS and secondary endpoints were PFS and ORR. Patients receiving cabozantinib had longer OS (10.2 vs. 8.0 months; HR =0.76; 95% CI: 0.63–0.92; P=0.005). PFS was 5.2 vs. 1.9 months, and ORR was 4% and <1%, comparing cabozantinib and placebo, respectively (9). Grade 3 or 4 adverse events occurred in 68% of patients receiving cabozantinib with the most common observed being hand-foot skin reactions, hypertension, fatigue, diarrhea and increase in hepatic AST levels (9).

Regorafenib

The RESORCE trial introduced regorafenib as a potential second-line agent for advanced HCC in patients who had progressed on sorafenib (10). Regorafenib is a multikinase inhibitor that targets EGFR and VEGF receptors. The phase III, randomized, double-blinded trial selected 567 Child-Pugh A patients who had been on sorafenib and tolerated the drug for at least 20 out of the 28 days before discontinuation and assessed overall survival compared with placebo (10). Patients were enrolled and randomized to receive regorafenib 160 mg daily vs. placebo. Median OS was 10.6 months with regorafenib vs. 7.8 months with placebo (HR =0.63, 95% CI: 0.50–0.79; P<0.0001). Grade 3 or 4 adverse events were hypertension, hand-foot skin reactions, fatigue, and diarrhea (10).

VEGF inhibitors

Insight into the pathogenesis of HCC has revealed the key role of VEGF and VEGFR signaling pathways in angiogenesis and tumor growth. The VEGF family of proteins are essential regulators in physiological and pathological angiogenesis (16). Their role as therapeutic targets in HCC was discovered when VEGF overexpression was evident in these tumors (17). With the understanding that a key step in tumor growth requires oxygen and nutrient delivery for sustained growth, it is of no surprise that as far back as 1971 the hypothesis was launched regarding targeting tumor angiogenesis as a potential therapeutic option (18). In HCC, heightened VEGF expression is seen and sorafenib as mentioned before also targets the VEGF signaling pathway via multikinase inhibition resulting in the therapeutic benefit well described. The modest benefit of sorafenib (relatively 3 months), however, led to the investigation of alternative pathways targeting VEGF inhibition and tumor angiogenesis (19).

Ramucirumab

Ramucirumab is a recombinant monoclonal IgG1 antibody and VEGF antagonist (17). In the randomized multicenter phase III REACH trial, ramucirumab was assessed as a second-line treatment option versus placebo in advanced HCC in patients whose disease had progressed on sorafenib. Even though the study did not meet its primary endpoint of OS vs. placebo (median OS 9.2 vs. 7.6 months), further analysis demonstrated that ramucirumab seemed to improve OS in patients with a higher baseline alpha-fetoprotein (AFP) level, shifting attention to the utility of AFP level as a potential biomarker in directing therapy. AFP has historically been used in the diagnosis and prognostication of HCC. Elevated AFP has been associated with elevated VEGFR expression, increased angiogenesis, and poor prognosis in HCC (17,20). REACH 2 was designed to investigate the benefit of ramucirumab in patients with a baseline AFP level of >400 ng/mL. In this randomized, double-blinded phase III trial, 292 patients were randomized to ramucirumab [197] vs. placebo [95]. Primary endpoint of OS was improved: 8.5 vs. 7.3 months (P=0.0199); secondary endpoints were also better: PFS: 2.8 vs. 1.6 months (P<0.0001); and disease control rate: 59.9% vs. 38.9% (P=0.0006) compared with placebo (21).

Bevacizumab

Bevacizumab, a humanized monoclonal antibody that binds VEGF-A is thought to reduce tumor vascularity and growth (Figure 2). Multiple phase II clinical trials have investigated bevacizumab as either monotherapy (22), combination therapy with EGFR inhibitor (23-26) and combination therapy with chemotherapy (capecitabine, oxaliplatin, gemcitabine) (19,27-29). A systematic review that analyzed 8 phase II clinical trials evaluating bevacizumab as single or combination therapy in advanced HCC concluded that bevacizumab may be effective and tolerated. Unfortunately, limitations based on sample size, lack of randomization, and publication bias resulted in none of these trials being able to translate into larger, phase III studies (22). Ongoing research led to the evaluation of combination anti-PDL-1 inhibition with bevacizumab which launched the groundbreaking IMBrave150 phase III study, discussed below.

Figure 2.

Mechanism of action of anti-vascular endothelial growth factor monoclonal antibodies. The figure is reused from the article below Gao F, Yang C. Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic. Curr Cancer Drug Targets 2020;20:3-18.

Immunotherapy

HCC is commonly referred to as an immunogenic tumor due to its development in chronically inflamed livers from both viral and non-viral causes (30). In addition, expression of tumor-associated antigens and specific gene mutations giving rise to private neoantigens contribute to HCC immunogenicity (31). Research into HCC’s tumor microenvironment (TME) has opened the door to novel immunomodulation therapeutic options in advanced HCC. An intricate microenvironment exists between the chronic inflammation sustained from hepatitis viruses and the production of cytokines and growth factors within the parenchyma (30). The liver has also been known to have an intrinsic immunosuppressive microenvironment due to weak T cell activation from low expressions of tumor related antigens. The body’s anti-tumor immune activity is mostly provided by T cells and upregulation of programmed cell death ligand 1 (PD-L1) on tumor cells has contributed to the immuno-suppressive microenvironment (32). Immune checkpoints are co-inhibitory surface glycoproteins that primarily play the role of preventing T cell immune overactivation during states of inflammation and infection. This limits collateral tissue damage in physiological states but their expression is a key mechanism driving T cell exhaustion and immune tolerance in the tumor microenvironment. CTLA-4 and PD-1 are well recognized immune checkpoints in cancer expressed on activated T cells and other immune cells. CTLA-4 is also expressed on T regulatory cells (Tregs) and upon antigen presentation exerts its inhibitory effect by counteracting T cell co stimulation. This is achieved via competitive binding of CD80 and CD86 receptors on antigen presenting cells leading to diminished CD28 activation and immune evasion (33-37). Downregulation of the CD28 pathway is also affected by PD-1 binding to its ligands, PD-L1 and PD-L2 inhibiting CD8⁺ T cell activation and leading to immune suppression (Figure 3). Cancer cells utilize this mechanism to evade immune surveillance by expressing PD-L1 and PD-L2. A state of T cell exhaustion is reached through chronic antigen exposure in the tumor microenvironment evident by upregulation of PD-L1 in antigen presenting cells and tumor cells induced by PD-1 expression on reactive T cells (34,38,39). This leads to tumor infiltration, less efficient tumor control and as a result poorer outcome (40).

Figure 3.

Mechanism of immune checkpoints in HCC in absence (A) and presence (B) of ICI. The figure is reused from the article below Mohr R, Jost-Brinkmann F, Özdirik B, et al. Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. Front Immunol 2021;12:652172. APC, antigen presenting cell; CTLA-4, cytotoxic T-lymphocyte associated protein 4; HCC, hepatocellular carcinoma; ICI, immune checkpoint inhibitor; MHC, major histocompatibility complex; PD-1, programmed cell death 1 protein; PD-L1, programmed death-ligand 1; TCR, T cell receptor.

Over the last 5–10 years we have appreciated the evolution of immunotherapy and its positive outcomes in the treatments of multiple cancers including melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck cancers, Hodgkin’s disease, and others. In HCC tumor antigen therapy, immune checkpoint inhibitors, and adoptive cell transfer (ACT) have all been investigated (41). The potential use of immunotherapy in HCC was first investigated with tremelimumab, a cytotoxic T lymphocyte antigen 4 (CTLA4) human monoclonal IgG2 antibody. This multicenter phase II trial evaluated 21 patients with HCC and chronic hepatitis C who were treated with tremelimumab (42). A good safety profile was observed and a subsequent median TTP of 6.5 months (95% CI, 3.95–9.14), and median OS of 8.2 months (95% CI, 4.64–21.34) were observed. Accelerated FDA approval was obtained for nivolumab [an IgG4 monoclonal antibody targeting programmed cell death 1 (PD-1)] in the treatment of HCC in patients previously treated with sorafenib. This came after the milestone CheckMate-040 trial, which evaluated nivolumab monotherapy, reported 70% of patients previously treated with sorafenib achieved an ORR of 20% in the dose-escalation cohort and 15% in the dose-expansion cohort [with complete responses (CR) achieved in each group]; stable disease was shown in 43.2% and 45.5%, respectively. Efficacy was seen irrespective of PD-1 expression on tumor cells, hepatitis B or C viral infection (43). This led to the phase III CheckMate-459 study which evaluated nivolumab in the first-line setting but did not meet its primary endpoint of OS even though showing clinically meaningful improvements in OS, ORR, and CR (44) (Table 3). Pembrolizumab, another anti-PD1 monoclonal antibody, also demonstrated clinical antitumor activity and safety in the phase II KEYNOTE-224 trial in patients previously treated with sorafenib in advanced HCC. The phase III KEYNOTE 240 randomized trial evaluated pembrolizumab and showed improved OS compared with placebo (HR =0.78; one-sided P=0.0238) and PFS (HR =0.78; one-sided P=0.0209) but failed to reach statistical significance (46).

Table 3. Single agent immunotherapy trials in HCC.

Trial	Author	No. of patients	Study arm	ECOG	Child-Pugh score	Primary end point
	Sangro et al. (42)	21	Tremelimumab in chronic hepatitis C	0 or 1	A or B	Safety and efficacy: TTP was 6.48 months (95% CI, 3.95–9.14) and median OS was 8.2 months (95% CI, 4.64–21.34)
	Wainberg et al. (45)	40	Durvalumab (phase I/II)	0 or 1	A	Safety and efficacy: median OS 13.2 months (6.3–21.1); ORR 10.3% (2.9–24.2)
Keynote-240	Finn et al. (46)	413	Pembrolizumab vs. placebo (phase III, second-line setting)	0 or 1	A	OS: 13.9 months (95% CI, 11.6–16.0) for pembro vs. 10.6 months (95% CI, 8.3–13.5) for placebo (HR =0.781; 95% CI, 0.611–0.998; P=0.0238); PFS: 3.0 months (95% CI, 2.8–4.1) vs. 2.8 months (95% CI, 1.6–3.0)
CheckMate-459	Yau et al. (44)	743	Nivolumab vs. sorafenib (phase III, first-line setting)			OS: 16.4 months for nivolumab vs. 14.7 months for sorafenib (HR =0.85; 95% CI, 0.72–1.02; P=0.0752); ORR: 15% with nivolumab (14 patients with CR) vs. 7% with sorafenib (5 patients with CR)

HCC, hepatocellular carcinoma; ORR, objective response rate; OS, overall survival; HR, hazard ratio; CR, complete response.

Chimeric antigen receptor T cells (CAR-T), a form of ACT therapy, has shown promising results in the treatment of CD19⁺ hematological malignancies. Its utility in solid tumors, and specifically HCC, has unfortunately not been as promising; either due to a lack of efficacy or due to intolerable toxicities. The concept behind CAR-T immunotherapy is that tumor cells express antigens or aberrant proteins that can be targeted with genetically engineered T cells (41,47).

Preclinical data in HCC tumors have shown promising results with various tumor associated antigens that could be potential targets for CAR-T therapy, specifically GPC-3, MUC-1, EpCAM, CEA and AFP (47). Future directions would be to translate some of these potential outcomes into clinical trials.

Combination therapy

The most recent and remarkable advance in HCC has been with combination therapy atezolizumab, an anti PD-L1 antibody, and bevacizumab, a VEGF monoclonal antibody for unresectable or metastatic HCC (48). VEGF overexpression has been evident in the tumor microenvironment contributing to immune evasion and tolerance in tumors. VEGF is primarily involved in angiogenesis which paradoxically leads to a hypoxic and acidotic TME associated with recruitment of immunosuppressive cells such as Tregs (49). VEGF also increases PD-1 expression of tumor infiltrating T-cells (50). VEGF mediated immune suppression is reduced by targeting VEGF and the addition of immune checkpoint inhibitors results in an enhanced immune reactivation via upregulation of T cell activity and infiltration into tumor cells (48). This combination was evaluated in the phase III IMbrave150 trial that randomized 501 patients who had not received prior systemic treatment in a 2:1 ratio to atezolizumab-bevacizumab vs. sorafenib. The study showed statistically significant improvement in OS at 12 months was 67.2% (95% CI, 61.3–73.1%) with atezolizumab–bevacizumab and 54.6% (95% CI, 45.2–64.0%) with sorafenib (51). PFS HR was 6.8 months compared with 4.3 months with sorafenib 0.59 (95% CI, 0.47–0.76; P<0.0001) (48). Secondary endpoints further demonstrated ORR of 27.3% (95% CI, 22.5–32.5%) with atezolizumab–bevacizumab and 11.9% (95% CI, 7.4–18.0%) with sorafenib according to RECIST 1.1. This promising breakthrough has led to this combination becoming the preferred approach for HCC management with FDA approval and is now recommended as first-line therapy in advanced HCC per the 2020 ASCO guidelines (52). The adverse event profile of this combination was consistent with the known safety profile of each agent and the underlying disease. Grade 3–4 hypertension was observed in 15.2% of patients and less commonly proteinuria, fatigue, elevation in AST levels were also reported. Approximately 15% of patients in the atezolizumab-bevacizumab group discontinued treatment based on adverse events compared to 10% in the sorafenib group. Gastrointestinal adverse events were the most common reported reason for discontinuation. Bleeding is a known adverse event of bevacizumab attributed to its anti-angiogenic effects. Upper gastrointestinal bleeding with the potential for a life-threatening bleed is a common complication of cirrhosis and in the atezolizumab-bevacizumab group this was observed in 7% of patients compared to 4.5% on sorafenib (51). The major caveat to note is that patients must have no esophagogastric varices (or varices should have been adequately treated prior to treatment initiation) due to increased risk of catastrophic bleeding with bevacizumab.

Further research into potential combination therapies continue to primarily involve immunomodulation by incorporating ICI’s with either TKI’s, alternative ICI/anti-VEGF combinations or dual immune checkpoint inhibition. Preclinical data into combination ICI and TKI’s revealed the immunomodulatory effects of TKI’s, specifically lenvatinib shown to reduce tumor-associated macrophages (TAMs) and increased the percentage of activated CD8⁺ T cells secreting interferon (IFN)-γ (53). When combined with PD-1 blockade anti-tumor activity was enhanced via the IFN signaling pathway (53). The phase Ib KEYNOTE-524 identifies pembrolizumab and lenvatinib as a first-line treatment option in advanced HCC. The latest data from 2020 ASCO meeting showed median OS was 22.0 months (95% CI, 20.4–NE), the median PFS was 9.3 months (95% CI, 7.1–9.7), and the ORR was 46% (95% CI, 36–56.3%), CR reaches 11% (54). Grade ≥3 treatment related adverse effects occurred in 67% of patients consistent with the known toxicities of each drug. This promising therapeutic combination has launched the LEAP-002 global phase III evaluating pembrolizumab-lenvatinib against lenvatinib monotherapy (55). Recently published data evaluated combination TKI/anti-PD1 therapy as a downstaging strategy to convert previously unresectable HCC to resectable HCC. Treatment utilized either pembrolizumab-lenvatinib and camrelizumab-apatinib in 63 patients and 15% of these patients were able to receive curative resection (56). Camrelizumab, an anti-PD-1 and apatinib, an anti-VEGF-2 TKI was further evaluated in the RESCUE trial. This phase II study enrolled 190 patients with advanced HCC who were either treatment naïve or refractory/intolerant to 1^st or 2^nd line therapy. The ORR was 34.3% (95% CI, 23.3–46.6%) in the first-line cohort and 22.5% (95% CI, 15.4–31.0%) in the second-line cohort. Median PFS in both cohorts was 5.7 months (95% CI, 5.4–7.4) and 5.5 months (95% CI, 3.7–5.6) respectively. Survival rate at 12-months was 74.7% (95% CI, 62.5–83.5%) in the 1^st line cohort and 68.2% (95% CI, 59.0–75.7%) in those with prior 2^nd line therapy. A proportion of 77% of patients experienced grade ≥3 therapy related adverse events the most common being hypertension (57). This promising outcome has translated to the phase III trial currently active (NCT03764293). The phase Ib VEGF Liver 100 trial evaluated avelumab, an anti-PD-L1 antibody with axitinib, a selective TKI to VEGF 1, 2, 3. Overall this combination was well tolerated with reported adverse effects consistent with each drug such as hypertension, hand-foot skin reactions, hypo- and hyperthyroidism. No grade 4/5 treatment related adverse events were reported. In the 22 patients that were evaluated tumor shrinkage was observed in 15 (68.2%) and 16 (72.7%) patients, ORR was 13.6% (95% CI, 2.9–34.9%) and 31.8% (95% CI, 13.9–54.9%) by RECIST and mRECIST, respectively (58).

Conclusions

Over the past 15 years, we have made remarkable progress in the management of advanced HCC—from sorafenib dominating as the sole option in the first-line setting to now having three different first-line treatment options (atezolizumab-bevacizumab, sorafenib and lenvatinib). Second-line treatment options have also expanded to cabozantinib, regorafenib, ramucirumab (AFP >400 ng/mL). The immune checkpoint inhibitors nivolumab and pembrolizumab have been recommended as second-line treatment in patients intolerant to TKI’s (50). With the success of combination azetolizumab-bevacizumab, ongoing studies are currently looking into more combination therapies with ICI’s as the backbone. This includes pembrolizumab-lenvatinib in the LEAP-002 phase III (55), atezolizumab-cabozantinib in the COSMIC-012 phase III (59), and doublet immune checkpoint inhibition with nivolumab-ipilimumab in the Checkmate-9DW trial (60) and durvalumab-tremelimumab in the HIMALAYA phase III trial (61). It is with great expectation that as research continues into investigating various targeted therapeutic options in HCC, more therapies will become available that translate into longer survival benefits.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.